[1]Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review[J]. Cancer,2004,101(3):613-619.[2]Asa SL, Ezzat S. The pathogenesis of pituitary tumours[J]. Nat Rev Cancer,2002,2(11):836-849.[3]Lania A, Spada A. G-protein and signalling in pituitary tumours[J]. Horm Res,2009,71(Suppl 2):95-100.[4]Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: focus on G-protein mutations[J].Exp Biol Med (Maywood),2003,228(9):1004-1017.[5]Lin Y, Jiang XF, Shen Y, et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors[J]. Endocr Relat Cancer,2009,16(1):301-310.[6]Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG)[J]. Mol Endocrinol, 1997,11(4):433-441.[7]Salehi F, Kovacs K, Scheithauer BW, et al. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update[J]. Endocr Relat Cancer,2008,15(3):721-743.[8]Tong Y, Tan Y, Zhou C, et al. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition[J]. Oncogene,2007,26(38):5596-5605. [9]Chesnokova V, Zonis S, Rubinek T, et al. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth[J]. Cancer Res,2007,67(21):10564-10572.[10]Filippella M, Galland F, Kujas M, et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study[J]. Clin Endocrinol (Oxf),2006,65(4):536-543. [11]Abbud RA, Takumi I, Barker EM, et al. Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice[J]. Mol Endocrinol,2005,19(5):1383-1391.[12]Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1[J]. Science,1997,276(5311):404-407.[13]Agarwal SK, Ozawa A, Mateo CM, et al. The MEN1 gene and pituitary tumours[J]. Horm Res,2009,71(Suppl 2):131-138.[14]Cazabat L, Guillaud-Bataille M, Bertherat J, et al. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas[J]. Horm Res,2009,71(3):132-141.[15]Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas[J]. J Clin Endocrinol Metab, 2008,93(6):2390-2401.[16]Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene[J]. Science,2006,312(5777):1228-1230.[17]Kirschner LS. PRKAR1A and the evolution of pituitary tumors[J].Mol Cell Endocrinol,2010,326(1-2):3-7.[18]Yin Z, Williams-Simons L, Parlow AF, et al. Pituitary- specific knockout of the Carney complex gene prkar1a leads to pituitary tumorigenesis[J]. Mol Endocrinol,2008,22(2):380-387.[19]Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update[J].Hum Mol Genet,2007,16(1):R73-R79.[20]Marinoni I, Pellegata NS. p27kip1: a new multiple endocrine neoplasia gene [J].Neuroendocrinology,2011,93(1):19-28.[21]Matoso A, Zhou Z, Hayama R, et al. Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia[J].Carcinogenesis,2008,29(3):620-628.[22]Chesnokova V, Zonis S, Kovacs K, et al. p21Cip1 restrains pituitary tumor growth[J]. Proc Natl Acad Sci USA,2008, 105(45):17498-17503.[23]Zhang X, Sun H, Danila DC, et al. Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis[J].J Clin Endocrinol Metab,2002,87(4):1262-1267.[24]Zhao J, Dahle D, Zhou Y, et al. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors[J].J Clin Endocrinol Metab,2005,90(4):2179-2186.[25]Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas[J]. Best Pract Res Clin Endocrinol Metab,2009,23(5):525- 541.[26]Asa SL, Ezzat S. The pathogenesis of pituitary tumors[J]. Annu Rev Pathol,2009,4(4):97-126.[27]Ezzat S, Zheng L, Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia[J]. Mol Endocrinol,2004,18(10):2543-2552.[28]Ezzat S, Yu S, Asa SL. The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility[J]. Mol Endocrinol,2005,19(4):1004-1011.[29]Ezzat S, Asa SL. The emerging role of the Ikaros stem cell factor in the neuroendocrine system[J].J Mol Endocrinol,2008, 41(2):45-51. [30]Cakir M, Grossman AB. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis[J]. Expert Opin Ther Targets,2009,13(9):1121-1134.[31]Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of Raf/MEK/ERK and PI3K/Akt/mTOR pathways in pituitary adenomas and their effects on downstream effectors[J]. Endocrine Related Cancer,2009,16(4):1329-1338. |